WILLIAM R. KEMP, M.D.

Plain English
This study looked at the use of statins, which are common medications for lowering cholesterol, in treating metabolic dysfunction-associated steatotic liver disease (MASLD). It found that statins could help not only with heart health but might also be beneficial for MASLD patients, who make up about 38% of adults globally. Understanding how statins can be effectively used in this way is important because MASLD can lead to serious health issues like liver cirrhosis and cancer. Who this helps: This benefits patients with MASLD and their doctors.

Plain English
This study looked at the impact of the COVID-19 pandemic on hospital admissions for alcohol-associated hepatitis (AAH) in Australia. Researchers found that between March 2020 and March 2021, there were significantly more admissions for AAH, with an average of 8 cases per month compared to 3 in the years before the pandemic. Additionally, 26% of these patients needed intensive care, and the average healthcare costs for AAH patients jumped from about $42,983 to $90,912 during this period. Understanding these increases is crucial for developing better strategies to prevent alcohol-related health issues in the future. Who this helps: This helps patients suffering from alcohol-related conditions and healthcare providers managing their care.

Plain English
This paper discusses new guidelines for diagnosing and managing portal hypertension, a serious complication of cirrhosis, developed by a group of 46 Australian healthcare professionals. They came up with 52 recommendations covering various aspects of care, including how to diagnose the condition and manage related issues like bleeding and nutritional needs. These guidelines are important because they aim to improve the health outcomes for patients with cirrhosis in Australia. Who this helps: Patients with cirrhosis and their healthcare providers.

Plain English
This study examined how two types of fatty liver diseases, MASLD and MAFLD, affect the risk of getting and dying from cancers outside the liver in regional Australia. Researchers followed over 2,700 adults for nearly 20 years and found that while neither disease increased the chances of dying from cancer, both were linked to a higher risk of developing colorectal cancer—specifically, by about 2.9 times for MASLD and 3.15 times for MAFLD, especially in women. This is important because it highlights the need for close monitoring of colorectal cancer risks in people with these liver conditions. Who this helps: This helps patients with fatty liver disease and their healthcare providers.

Plain English
This study looked at the healthcare costs for patients with metabolic (dysfunction)-associated fatty liver disease (MAFLD) compared to those with chronic hepatitis B (CHB) in a clinic in Melbourne, Australia. It found that among 310 MAFLD patients, nearly 27% had advanced liver damage (F3-4), which caused over half of the costs related to their care. In contrast, only 9% of the 261 CHB patients had advanced liver damage, resulting in significantly lower costs associated with hospital stays for CHB patients (6.1% for MAFLD vs. 0.4% for CHB). This matters because it shows that managing MAFLD is much more expensive, particularly due to hospitalizations, and emphasizes the need for better care management strategies to reduce costs and improve patient outcomes. Who this helps: This benefits patients living with MAFLD and healthcare providers managing their care.

Plain English
This study looked at how well blood tests can predict health outcomes in people with fatty liver disease in Australia. Researchers followed 1,324 participants with one type of fatty liver disease and 1,444 with another type, finding that over nearly 20 years, there were 298 deaths, mostly from heart disease and cancer. The tests used were good at predicting overall death risk but not very effective at identifying severe liver problems. Who this helps: This research benefits patients and doctors by providing insights into the effectiveness of non-invasive tests for assessing liver health.

Plain English
This study looked at how liver cancer (hepatocellular carcinoma, or HCC) is treated in different medical centers, finding that there is a lot of inconsistency and that many centers do not follow the best treatment guidelines. The researchers proposed new quality indicators to help measure and improve the standard of care and emphasized the importance of a national clinical quality registry to track progress. Improving how HCC is managed can lead to better patient outcomes and ensure more consistent care. Who this helps: This helps patients with hepatocellular carcinoma and the doctors treating them.

Plain English
This study looked at the long-term risk of death in people with two types of liver disease linked to metabolism: metabolic-associated fatty liver disease (MAFLD) and metabolic-associated steatotic liver disease (MASLD). Researchers found that MAFLD increases the risk of death by 39%, while MASLD does not significantly raise this risk. Additionally, people with metabolic issues like diabetes had higher chances of dying, especially from cancer (about 34%) and heart disease (around 30%). Who this helps: This research benefits patients with fatty liver disease and healthcare providers working to manage their conditions.

Plain English
This study looked at a test called rotational thromboelastometry (ROTEM) to see if it could predict how long patients with liver cirrhosis might survive without needing a liver transplant. Researchers followed 162 patients for about 3.5 years and found that those who eventually died or needed a transplant had lower clot firmness scores compared to those who survived (52 vs. 57 and 51 vs. 55). This matters because it shows that ROTEM can help identify patients at higher risk, which could improve their care. Who this helps: Patients with liver cirrhosis.

Plain English
This study focused on patients with primary sclerosing cholangitis (PSC), a rare liver disease often linked to inflammatory bowel disease (IBD), to better understand how their health-related quality of life (HRQOL) is affected. Researchers gathered information from 55 patients and found that most experienced significant fatigue, and poorer HRQOL was strongly associated with more severe liver disease, particularly in cases of advanced cirrhosis. This study is important because it highlights the real-life impact of PSC on patients' well-being, indicating that those with more severe liver conditions face greater challenges in their daily lives. Who this helps: This helps patients with PSC and their healthcare providers in managing the disease better.

Plain English
This study looked at the blood and liver samples of 266 obese people to find a way to identify those at high risk for a serious liver condition called metabolic-associated steatohepatitis (MASH). Researchers found 107 proteins that are different in people with MASH compared to those without liver issues and created a model (called the APASHA model) that can predict MASH with 88% accuracy. This is significant because it helps doctors identify at-risk patients without invasive testing, leading to earlier interventions and better health outcomes. Who this helps: This helps patients with obesity who are at risk for liver disease.

Plain English
This study looked at patients with severe liver cirrhosis who were admitted to intensive care units (ICUs) in Victoria, Australia, from 2007 to 2018. It found that 43.8% of these patients died within a year after their ICU stay, though this rate decreased slightly over the years. The researchers found that conditions like acute liver failure and severe liver disease made it more likely for patients to die in the hospital, while the severity of liver disease was more important for long-term survival among those who survived the hospital stay. Who this helps: This information is valuable for doctors caring for patients with liver cirrhosis, helping them understand risks and improve patient outcomes.

Plain English
This study looked at how exercise and nutrition can help older women with breast cancer tolerate chemotherapy better. Women aged 65 and older were divided into two groups: one group participated in weekly telehealth exercise sessions and received dietary guidance, while the other group just got supportive care materials. Initial results may show that the exercise and nutrition program helps these patients stay on track with their chemotherapy, which is important because it could lead to better treatment outcomes and improved quality of life. Who this helps: This helps older women with breast cancer.

Plain English
This study compared the costs of two medical procedures, TIPS and BRTO, used to prevent re-bleeding in patients with ruptured gastric varices. It found that the median cost for TIPS was AUD $11,922, while BRTO was much cheaper at AUD $3,632, making BRTO a more cost-effective option (p < 0.001). Understanding these costs is important as it helps healthcare providers make informed decisions about the best treatments for patients facing this serious condition. Who this helps: This benefits patients who are at risk of gastric re-bleeding, as well as doctors making treatment decisions.

Plain English
This study looked at the link between metabolic-associated fatty liver disease (MAFLD) and liver cancer (hepatocellular carcinoma or HCC) in Australia. It found that out of 313 newly diagnosed HCC patients, 77 had MAFLD, which is now as common as alcohol-related liver disease among these patients. Those with MAFLD were generally older (average age 73), more often female (40%), and less likely to have severe cirrhosis compared to patients without MAFLD, which suggests that we need new strategies for screening and treating this specific group. Who this helps: This helps patients with metabolic-associated fatty liver disease and liver cancer.

Plain English
This paper provides guidelines for measuring fat in the liver using ultrasound technology. It discusses three methods: the attenuation coefficient, backscatter coefficient, and speed of sound, which help estimate liver fat content by analyzing ultrasound data. Key points include the importance of following a standardized approach to get accurate measurements and acknowledging that the existing evidence is limited. Who this helps: This helps doctors and medical professionals who are treating patients with liver fat issues.

Plain English
This study looked at how regular MRI scans impact the survival of patients with primary sclerosing cholangitis (PSC). Researchers found that patients who received regular MRCP scans had a 71% lower risk of death compared to those who did not get regular scans, with 220 out of 298 patients in the study undergoing this surveillance. However, once patients were diagnosed with liver cancer, their survival rates did not differ between the groups. Who this helps: This benefits patients with PSC by highlighting the importance of regular MRI monitoring for better overall survival.

Plain English
This study updates guidelines for using a specific type of ultrasound called elastography to assess chronic liver disease. It highlights how well ultrasound can measure liver stiffness to determine the severity of liver damage and assess related conditions like high blood pressure in the liver. The findings emphasize its benefits and drawbacks in clinical settings to ensure better care for patients with liver issues. Who this helps: This helps patients with chronic liver conditions and their healthcare providers.

Plain English
This study looked at how different hospitals in Australia treat early-stage liver cancer and the impact on patient survival. Researchers found that patients treated at transplant centers received less aggressive upfront treatment, such as ablation, but had better survival rates, with a 29% lower risk of death compared to those at non-transplant centers. Understanding these differences is important because it can help improve treatment approaches and outcomes for liver cancer patients across the country. Who this helps: This helps patients with early-stage liver cancer.

Plain English
This study examined how fatty liver diseases, specifically non-alcoholic fatty liver disease (NAFLD) and metabolic-associated fatty liver disease (MAFLD), affect the risk of serious heart-related events in a group of people from regional Australia over a 20-year period. The researchers found that people with NAFLD had a 56% higher risk (1.56 times more likely), and those with MAFLD had a 51% higher risk (1.51 times more likely) of experiencing major cardiovascular events, like heart attacks or strokes, compared to those without these liver diseases. This is important because it highlights the need for regular heart health monitoring in patients with fatty liver disease, as they are at a greater risk of serious cardiovascular problems. Who this helps: This helps patients with fatty liver disease and their doctors in managing their heart health.

Plain English
This study focused on patients with cirrhosis, a serious liver condition, and investigated whether a test called Rotational Thromboelastometry (ROTEM) could predict bleeding events. Out of 162 patients, 19 experienced bleeding within a year, and those who bled had lower scores on key ROTEM measures, indicating weaker blood clots. This is important because it shows that ROTEM could help doctors identify patients at higher risk for bleeding, potentially leading to better care and preventive measures. Who this helps: Patients with cirrhosis and their doctors.

Plain English
This study explored how artificial intelligence (AI) can predict the return of liver cancer (hepatocellular carcinoma, or HCC) in patients after surgical treatment. Researchers analyzed data from 958 patients and found that their AI model could accurately predict recurrence by considering various individual factors, achieving an accuracy of about 86% in initial tests. This is important because it can help doctors develop personalized treatment plans to reduce the chances of cancer coming back by focusing on modifiable risk factors. Who this helps: Patients with liver cancer.

Plain English
This study looked at two treatment options for patients with small liver tumors called hepatocellular carcinoma (HCC): trans-arterial chemo-embolisation (TACE) and percutaneous ablation. Researchers found that both treatments resulted in similar survival rates over about three and a half years, with 115 patients in each group showing no significant difference in overall or liver-related survival. However, percutaneous ablation was more effective at achieving complete tumor removal initially (74% compared to 56%), but when additional treatments were considered, the difference in complete removal rates was not significant (86% vs. 80%). Who this helps: This research helps doctors decide between TACE and ablation for treating early-stage liver cancer in patients.

Plain English
This study looked at cirrhotic patients (those with liver disease) who were admitted to intensive care units (ICUs) in Australia and New Zealand between 2005 and 2017 due to infections. It found that while the chance of surviving such infections improved over time—hospital death rates dropped from 35.5% to a better-than-before outcome—these patients still had a higher mortality rate than other patients with infections without liver disease. Specifically, the death rate for cirrhotic patients with an additional condition called acute-on-chronic liver failure remained notably high at 52.2%, and showed no improvement. Who this helps: Patients with liver disease and their healthcare providers.

Plain English
This study looked at how liver stiffness measurements, taken using a special ultrasound technique called Fibroscan, can predict overall death rates in people with non-alcoholic fatty liver disease (NAFLD). The researchers analyzed the health records of over 6,300 patients and found that 217 of them died over an average follow-up period of 3 years. They discovered that higher liver stiffness (measured in kiloPascals) and older age were strongly linked to higher death rates, with a liver stiffness measurement of 10 kPa or more increasing the risk of death by more than twice. Who this helps: This helps patients with non-alcoholic fatty liver disease understand their risk of serious health outcomes and helps doctors improve patient care.

Plain English
Researchers tested a new rapid test called POC ALT1 to measure alanine aminotransferase (ALT) levels, which are important for checking liver health. In their study involving 731 adults with chronic liver disease, they found that the POC ALT1 test accurately identified high ALT levels, achieving a sensitivity of 97% and a specificity of 71%. This is significant because it can quickly determine which patients with chronic hepatitis B need treatment, helping to improve patient care. Who this helps: This benefits patients with chronic liver disease, particularly those with hepatitis B.

Plain English
This research paper looks at non-alcoholic fatty liver disease (NAFLD), which is a common condition that can lead to liver and heart problems. The study found that NAFLD is closely linked to serious health risks, particularly due to issues like insulin resistance. It emphasizes the need for better ways to identify patients at high risk for complications and highlights that there are currently limited effective treatments available. Who this helps: This information is beneficial for patients with NAFLD and their healthcare providers.

Plain English
This study looked at the results of creating a specialized clinic for patients with non-alcoholic fatty liver disease (NAFLD) in Australia. Over a little more than a year, 137 patients attended the clinic, and 81% of them were able to maintain or lose weight. Their liver health also improved, with key liver enzyme levels dropping significantly; for example, the average level of one liver enzyme went from 48 to 41 units, which is a meaningful reduction. This matters because it shows that a dedicated team can lead to better management of NAFLD, but patients still need more help with weight loss. Who this helps: This benefits patients with non-alcoholic fatty liver disease.

Plain English
This study looked at a new, quick test that measures a specific protein ratio in the blood to help diagnose liver cirrhosis, a serious condition related to liver damage. The test was shown to have a good accuracy, correctly identifying 79% of cirrhosis cases and helping to avoid unnecessary follow-up tests for 57% of patients. Specifically, people with cirrhosis had a higher protein ratio (0.9) than those without it (0.4), making this a promising tool for diagnosis. Who this helps: This helps patients with chronic liver disease by providing a faster and simpler way to diagnose cirrhosis.

Plain English
This study looked into how doctors manage blood transfusions for patients with cirrhosis before procedures. It found that there is a lot of inconsistency in these practices, with 50% of doctors saying their workplace lacks clear guidelines. For instance, 61% of doctors would give platelet transfusions before low-risk procedures when the platelet count is low, but practices varied widely between institutions and specialties. Who this helps: This research benefits doctors and healthcare providers who care for patients with cirrhosis, helping them improve their transfusion practices.

Plain English
This research examined how taking aspirin might affect the risk of developing liver cancer, specifically hepatocellular carcinoma (HCC). The analysis included 16 studies with almost 2.5 million people, finding that those who used aspirin had a 30% lower risk of developing HCC compared to those who didn't. However, in patients with cirrhosis, the effect of aspirin appeared to be less significant, and the research also noted a slight increase in bleeding events linked to aspirin use. Who this helps: This information helps patients at risk of liver cancer and their doctors in considering aspirin use for prevention.

Plain English
This study looked at how changing the name of fatty liver disease from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) affects how people understand and diagnose the condition. Researchers found that MAFLD is more common than NAFLD and is linked to a greater risk of death. This is important because it helps doctors better identify and treat patients at risk, ultimately improving health outcomes. Who this helps: Patients with fatty liver disease and their healthcare providers.

Plain English
This study looks at how to better manage blood transfusions for patients with cirrhosis who need invasive procedures, comparing a new method called Rotational Thromboelastometry (ROTEM) to standard practices. Researchers believe that using ROTEM will allow doctors to give fewer unnecessary blood products, such as fresh frozen plasma, while still preventing bleeding during procedures. They expect this approach will lead to a decrease in the number of transfusions needed without increasing the risk of any complications. Who this helps: This helps patients with cirrhosis undergoing invasive procedures by potentially reducing their need for blood transfusions.

Plain English
This study examined the rise of non-alcoholic fatty liver disease (NAFLD) in regional Victoria, Australia, over the past 15 years. Researchers found that the percentage of people with NAFLD increased from 32.7% to 38.8% and that obesity rates rose by 28%, with women experiencing a larger increase in NAFLD than men. This matters because the rise in NAFLD, closely linked to obesity and unhealthy eating habits, indicates a growing health problem that could lead to serious liver complications for many individuals. Who this helps: Patients with non-alcoholic fatty liver disease and their healthcare providers.

Plain English
This research paper focuses on primary sclerosing cholangitis (PSC), a serious liver disease where bile ducts become inflamed, which can lead to severe liver problems. The study found that while a common treatment called ursodeoxycholic acid helps improve liver function at certain doses (15-23 mg per kilogram per day), it does not extend the time a patient can live without needing a transplant. Future treatments being explored include altering gut bacteria through fecal transplants and new types of bile acids that have shown promise in early trials. Who this helps: This helps patients with primary sclerosing cholangitis and their doctors by providing insights into potential new treatments.

Plain English
This study looked at the effects of COVID-19 on pregnant women and their babies by examining four cases where mothers tested positive for the virus. Out of these cases, three babies did not survive, and all had abnormal placentas that showed signs of damage and infection from the virus. These findings highlight how COVID-19 can lead to serious complications during pregnancy and potentially harm fetal development. Who this helps: This helps doctors and pregnant patients understand the risks associated with COVID-19.

Plain English
This study looked at how well two different treatments—surgical removal of the tumor (resection) and a less invasive method that destroys the tumor (ablation)—work for patients with early liver cancer. They found that patients who had surgery lived longer and had fewer cancer relapses compared to those who had the ablation treatment. Specifically, among 156 matched patients, those who had surgery had better overall survival rates and were less likely to see the cancer return. Who this helps: This research benefits patients with early-stage liver cancer and their doctors by guiding treatment choices towards surgery for better outcomes.

Plain English
This study looked at how changing the name from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) affects the number of people diagnosed with the condition in a community in Australia. Researchers found that 47.2% of participants had MAFLD, an increase from 38.7% under the old name, and included 17.5% of participants who only qualified for MAFLD based on new criteria. This is important because it shows that more people may need attention and treatment for fatty liver disease than previously recognized. Who this helps: This helps patients with fatty liver disease and healthcare providers understanding the need for updated diagnosis criteria.

Plain English
This study looked at a nurse-led program in Melbourne that helped people with hepatitis C (HCV) access testing and treatment at community and primary care clinics. Out of 640 people who participated, 74% began treatment after testing positive for the virus, and an impressive 97.5% of those who completed treatment were cured. This approach shows that coordinating care through nurses can greatly improve treatment rates for hepatitis C, especially in community settings, though people who are homeless or lack stable housing may need more support to start treatment. Who this helps: This helps patients with hepatitis C, particularly those in community settings.

Plain English
This study looked at a noninvasive imaging test called F-FDG PET/CT to see if it can effectively diagnose acute graft-versus-host disease (GVHD) in the gastrointestinal tract after a stem cell transplant. Out of 51 patients with suspected acute GIT-GVHD, 23 (about 45%) had the disease confirmed by biopsy, especially in the colon. The results showed that F-FDG PET/CT had moderate effectiveness, with a sensitivity of 69% and a positive predictive value of 59%, helping doctors identify patients who may need further testing. Who this helps: This benefits patients who have undergone stem cell transplants and may experience complications like GVHD.

Plain English
This study looked at primary sclerosing cholangitis (PSC) in Australia, involving 413 patients who were followed for an average of nearly 15 years. It found that 41% of these patients developed cirrhosis, with 12% dying or needing a liver transplant during the study. PSC patients face a significantly higher risk of developing bile duct cancer compared to the general population, showing a 240-fold increase in risk, especially as they age or if they have other issues like inflammation in the intestines. Who this helps: This research benefits patients with PSC and their doctors by highlighting serious risks associated with the condition.

Plain English
This research focused on Hepatitis B, which is the main cause of liver cancer (HCC) globally. It found that people with chronic Hepatitis B have an annual risk of developing liver cancer of 0.4% if they don’t have cirrhosis and 2% to 3% if they do. Regular monitoring and antiviral treatments significantly reduce the chances of developing liver cancer and its return after treatment. Who this helps: This benefits patients with chronic Hepatitis B and their doctors.

Plain English
This study looked at liver nodules in patients with cirrhosis, focusing on how the severity of liver disease affects the risk of these nodules turning into liver cancer. Out of 147 monitored nodules, 25 (or 17%) turned into cancer over a median follow-up of about 38.5 months. The severity of liver disease, measured by the Child-Pugh score, was the only strong predictor of this transformation; patients with more severe disease (Child-Pugh B and C) had much higher risks—10 times and over 32 times greater, respectively, compared to those with milder disease (Child-Pugh A). Who this helps: This information benefits doctors and patients with cirrhosis by helping them understand the risks associated with liver nodules.

Plain English
This research focused on improving electronics used in space by making them more resistant to radiation damage. The scientists developed a new type of transistor called carbon nanotube field-effect transistors (CNFETs), which showed exceptional resistance to radiation, withstanding over 10 million rad (a measure of radiation exposure) without failing. This is important because it means that electronics can last longer in space, making ambitious missions more feasible without the risk of technology breaking down. Who this helps: This benefits engineers and scientists designing electronics for space missions.

Plain English
This study looked at patients with two small liver tumors called hepatocellular carcinoma (HCC) to see how they fared over time. Out of 104 patients, 36 died and 25 received liver transplants, with survival rates after 1, 3, and 5 years being 93%, 66%, and 62%, respectively, for all patients. The findings highlight that patients with two small HCC generally have poor long-term survival without a transplant, suggesting that all such patients should be considered for this option. Who this helps: This helps patients with multiple small liver tumors and their doctors in making treatment decisions.